Clinical Trials Logo

Non-Alcoholic Steatohepatitis clinical trials

View clinical trials related to Non-Alcoholic Steatohepatitis.

Filter by:

NCT ID: NCT02530138 Recruiting - Clinical trials for Non Alcoholic Steatohepatitis

The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver

Start date: August 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Introduction: Currently, Nonalcoholic Fatty Liver Disease (NAFLD) is the most common liver disease in the world. The only approved treatment for it is lifestyle modification and weight loss; however, there is no evidence for patients with normal or low body mass index (BMI). The aim of this study is to evaluate the efficacy of symbiotic supplementation in NAFLD patients with normal or low BMI. Methods and analysis: In this randomized, double-blind, placebo-controlled clinical trial protocol, 21 cases and 21 controls will be individually matched based on age and sex. This 42 patients with NAFLD will be supplemented twice daily for 28 wk with either a synbiotic or a placebo capsule. Both groups will be advised to follow an energy balanced diet and physical activity recommendations.

NCT ID: NCT02075164 Recruiting - Clinical trials for Non-alcoholic Fatty Liver Disease

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

Start date: May 2013
Phase: N/A
Study type: Interventional

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of the general population. Moreover, NAFLD is an important risk factor for progression of diabetes and atherosclerosis. However, the pathomechanisms determining disease progression are poorly understood. The overall aim of this project is to test the central hypothesis that excessive fructose consumption provides a multiple metabolic hit in the pathogenesis and progression of NAFLD/NASH by impairment of hepatic lipid homeostasis and mitochondrial function resulting in hepatic lipotoxicity with inflammasome activation and disturbed interorgan cross-talk among insulin sensitive tissues.

NCT ID: NCT01617772 Recruiting - Clinical trials for Non-alcoholic Steatohepatitis

Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis

NALCAT
Start date: January 1, 2016
Phase: Phase 2
Study type: Interventional

The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin, L-Carnitine monotherapy on liver transaminases and liver elasticity in NASH patients.

NCT ID: NCT01056133 Recruiting - Clinical trials for Non-alcoholic Fatty Liver Disease

Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of Omega-3 Fish oil supplementation on hepatic gene expression in patients with Non Alcoholic Steatohepatitis (NASH). In addition, effects of fish oil on intestinal microbiota will be assessed.